Quarterly report · Q2
3101.TEDINET S100S6NA
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥199.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥399.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥201.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥2.4bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥7.9bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.0bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥6.6bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.8bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥3.1bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥14.8bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.0bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥655m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥11.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥11.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥577.2bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥588.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥541.2bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥355.4bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥367.5bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥221.8bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥221.4bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥207.0bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥29.9bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥60.7bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥29.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥60.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥28.1bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥10.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥12.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥26.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥36.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥16.8bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥15.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥61.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥5.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥22.82 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.6 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7.37 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.35 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.67 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 33.0% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.8% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥14.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥4.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥9.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥411m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥16.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥16.7bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥2.4bn |
| jpcrp040300-q2r_E00525-000Life Sciencereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥16.6bn |
| jpcrp040300-q2r_E00525-000Life Sciencereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥16.6bn |
| jpcrp040300-q2r_E00525-000Life Sciencereportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥7m |
| jpcrp040300-q2r_E00525-000Life Sciencereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E00525-000Real Estatereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E00525-000Real Estatereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E00525-000Real Estatereportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥582m |
| jpcrp040300-q2r_E00525-000Real Estatereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥971m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥201.9bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥194.8bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥7.1bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥216.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥199.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥16.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥4.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥12.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥4.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥184m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥10.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥10.6bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥1.9bn |
| jpcrp040300-q2r_E00525-000Life Sciencereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥19.3bn |
| jpcrp040300-q2r_E00525-000Life Sciencereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥19.3bn |
| jpcrp040300-q2r_E00525-000Life Sciencereportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥17m |
| jpcrp040300-q2r_E00525-000Life Sciencereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥5.4bn |
| jpcrp040300-q2r_E00525-000Real Estatereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.2bn |
| jpcrp040300-q2r_E00525-000Real Estatereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E00525-000Real Estatereportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥188m |
| jpcrp040300-q2r_E00525-000Real Estatereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥805m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥199.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥196.8bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥211.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥201.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥10.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥9.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 515
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes regarding promissory notes due on balance sheet date (text) | CurrentQuarterInstant | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding insurance income (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Disclosure of changes etc in reportable segments (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |